Literature DB >> 26038432

Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography.

Keiko Ryo1, Akiko Goda1, Tetsuari Onishi1, Antonia Delgado-Montero1, Bhupendar Tayal1, Hunter C Champion1, Marc A Simon1, Michael A Mathier1, Mark T Gladwin1, John Gorcsan2.   

Abstract

BACKGROUND: Adverse right ventricular (RV) remodeling has significant prognostic and therapeutic implications to patients with pulmonary hypertension (PH). However, differentiating RV adaption from adverse remodeling associated with poor outcomes is difficult. We hypothesized that novel 3-dimensional (3D) wall motion tracking echocardiography can differentiate morphological features of RV adaption from adverse remodeling heralding an unfavorable short-term prognosis in patients with PH. METHODS AND
RESULTS: We studied 112 subjects: 92 patients with PH and 20 normal controls with 3D wall motion tracking for RV end-systolic volume index (ESVi), RV ejection fraction (EF), and RV global area strain. Patients with PH also had invasive hemodynamic measurements. Pressure-volume relations classified patients with PH into 3 groups, such as RV adapted, RV adapted-remodeled, and RV adverse-remodeled. The predefined combined end point was PH-related hospitalization, death, or lung surgery (lung transplantation or pulmonary endarterectomy) during 6 months. The 92 patients with PH had significantly larger RV volumes, lower RVEF and global area strain than normal controls as expected. Patients with PH classified as RV adapted (ESVi, ≤72 mL/m(2)) had a more favorable clinical outcome than those classified as RV adapted-remodeled (ESVi, 73-113 mL/m(2)) or RV adverse-remodeled (ESVi, ≥114 mL/m(2)): hazard ratio, 0.15; 95% confidence intervals, 0.07 to 0.39; P<0.0001. RV adverse-remodeled patients (ESVi, ≥114 mL/m(2)) had worse short-term outcome than the RV adapted-remodeled patients: hazard ratio, 2.2; 95% confidence interval, 0.91 to 5.39; P=0.04.
CONCLUSIONS: Quantitative 3D echocardiography in patients with PH demonstrated morphological subsets of RV adaption and remodeling associated with clinical outcomes.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  echocardiography; outcomes assessment; pulmonary hypertension

Mesh:

Year:  2015        PMID: 26038432     DOI: 10.1161/CIRCIMAGING.114.003176

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  18 in total

1.  Comprehensive Right-Sided Assessment for Transcatheter Aortic Valve Replacement Risk Stratification: Time for a Change.

Authors:  João L Cavalcante; Marc A Simon; Stephen Y Chan
Journal:  J Am Soc Echocardiogr       Date:  2017-01       Impact factor: 5.251

2.  The value of three-dimensional echocardiography in risk stratification in pulmonary arterial hypertension: a cross-sectional study.

Authors:  Bing-Yang Liu; Wei-Chun Wu; Qi-Xian Zeng; Zhi-Hong Liu; Li-Li Niu; Yue Tian; Qin Luo; Zhi-Hui Zhao; Rui-Lin Quan; Jing-Ru Lin; Hao Wang; Jian-Guo He; Chang-Ming Xiong
Journal:  Int J Cardiovasc Imaging       Date:  2019-12-18       Impact factor: 2.357

3.  Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models.

Authors:  Myriam Amsallem; Andrew J Sweatt; Marie C Aymami; Tatiana Kuznetsova; Mona Selej; HongQuan Lu; Olaf Mercier; Elie Fadel; Ingela Schnittger; Michael V McConnell; Marlene Rabinovitch; Roham T Zamanian; Francois Haddad
Journal:  Circ Cardiovasc Imaging       Date:  2017-06       Impact factor: 7.792

4.  Diagnostic and prognostic value of right ventricular eccentricity index in pulmonary artery hypertension.

Authors:  Lili Wang; Xiaoling Chen; Ke Wan; Chao Gong; Weihao Li; Yuanwei Xu; Jie Wang; Juan He; Bi Wen; Yuchi Han; Rui Zeng; Yucheng Chen
Journal:  Pulm Circ       Date:  2020-04-09       Impact factor: 3.017

5.  Feature-Tracking MRI Fractal Analysis of Right Ventricular Remodeling in Adults with Congenitally Corrected Transposition of the Great Arteries.

Authors:  Masateru Kawakubo; Michinobu Nagao; Umiko Ishizaki; Yumi Shiina; Kei Inai; Yuzo Yamasaki; Masami Yoneyama; Shuji Sakai
Journal:  Radiol Cardiothorac Imaging       Date:  2019-10-31

6.  Right ventricular strain and volume analyses through deep learning-based fully automatic segmentation based on radial long-axis reconstruction of short-axis cine magnetic resonance images.

Authors:  Masateru Kawakubo; Daichi Moriyama; Yuzo Yamasaki; Kohtaro Abe; Kazuya Hosokawa; Tetsuhiro Moriyama; Pandji Triadyaksa; Adi Wibowo; Michinobu Nagao; Hideo Arai; Hiroshi Nishimura; Toshiaki Kadokami
Journal:  MAGMA       Date:  2022-05-18       Impact factor: 2.310

Review 7.  Right heart imaging in patients with heart failure: a tale of two ventricles.

Authors:  Myriam Amsallem; Tatiana Kuznetsova; Kate Hanneman; Andre Denault; François Haddad
Journal:  Curr Opin Cardiol       Date:  2016-09       Impact factor: 2.161

8.  Right ventricular septomarginal trabeculation hypertrophy is associated with disease severity in patients with pulmonary arterial hypertension.

Authors:  Yang Dong; Jiayu Sun; Dan Yang; Juan He; Wei Cheng; Ke Wan; Hong Liu; Andreas Greiser; Xiaoyue Zhou; Yuchi Han; Yucheng Chen
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-31       Impact factor: 2.357

9.  Use of Tricuspid Annular Plane Systolic Excursion/Pulmonary Artery Systolic Pressure As a Non-Invasive Method to Assess Right Ventricular-PA Coupling in Patients With Pulmonary Hypertension.

Authors:  Michael J Bashline; Marc A Simon
Journal:  Circ Cardiovasc Imaging       Date:  2019-09-10       Impact factor: 7.792

10.  Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study.

Authors:  Maurice Beghetti; Rolf M F Berger; Damien Bonnet; Simon Grill; Catherine Lesage; Jean-Christophe Lemarie; D Dunbar Ivy
Journal:  Front Pediatr       Date:  2021-06-16       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.